RNA‐binding motif protein 39 (RBM39): An emerging cancer target
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
RNA‐binding motif protein 39 (RBM39) is an RNA‐binding protein involved in transcriptional co‐regulation and alternative RNA splicing. Recent studies have revealed that RBM39 is the unexpected target of aryl sulphonamides, which act as molecular glues between RBM39 and the DCAF15‐associated E3 ubiquitin ligase complex leading to selective degradation of the target. Loss of RBM39 leads to aberrant splicing events and differential gene expression, thereby inhibiting cell cycle progression and causing tumour regression in a number of preclinical models. Many clinical studies have shown that aryl sulphonamides were well tolerated, but their clinical performance was limited due to an insufficient understanding of the target, RBM39 biology and a lack of predictive biomarkers. This review summarises the current knowledge of RBM39 function and discusses the therapeutic potential of this spliceosome target in cancer therapy. LINKED ARTICLES: This article is part of a themed issue on New avenues in cancer prevention and treatment (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.12/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UniProt: a worldwide hub of protein knowledge
The UniProt Consortium (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1049 · Cited by 7,698
Alternative isoform regulation in human tissue transcriptomes
Wang, E. T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., Kingsmore, S. F., Schroth, G. P., & Burge, C. B. (2008) · Nature · doi:10.1038/nature07509 · Cited by 5,181
Pan, Q., Shai, O., Lee, L. J., Frey, B. J., & Blencowe, B. J. (2008) · Nature Genetics · doi:10.1038/ng.259 · Cited by 3,951
Next-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054 · cited 1×
“Regions with reduced oxygen availability (hypoxia) are commonly found in tumours and associated with poor clinical outcomes in patients (Jing et al., 2019).”
BackgroundDrugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
Development of targeted protein degradation therapeutics
Chamberlain, P. P., & Hamann, L. G. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0362-y · Cited by 489 · cited 1×
“Recent progress in proteolysis-targeted chimaeras (PROTACs) and molecular glues provide novel approaches to target proteins that are challenging for conventional methods (Chamberlain & Hamann, 2019).”
BackgroundSelective degradation of splicing factor CAPERα by anticancer sulfonamides
Uehara, T., Minoshima, Y., Sagane, K., Sugi, N. H., Mitsuhashi, K. O., Yamamoto, N., Kamiyama, H., Takahashi, K., Kotake, Y., Uesugi, M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2363 · Cited by 396 · cited 33×
“It induces RBM39 degradation by promoting RBM39 polyubiquitination and proteasomal degradation in a DCAF15-dependent manner (Figure 3) (Han et al., 2017; Uehara et al., 2017).”
BackgroundMethodResultInfluentialObeng, E. A., Chappell, R. J., Seiler, M., Chen, M. C., Campagna, D. R., Schmidt, P. J., Schneider, R. K., Lord, A. M., Wang, L., Gambe, R. G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.006 · Cited by 380
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia
Wang, E., Lu, S. X., Pastore, A., Chen, X., Imig, J., Chun-Wei Lee, S., Hockemeyer, K., Ghebrechristos, Y. E., Yoshimi, A., Inoue, D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.010 · Cited by 338 · cited 32×
“This trial collected data from 37 patients with relapsed or heavily treated AML and one patient with high-risk myelodysplastic syndrome.”
BackgroundInfluentialDiscovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle
Owa, T., Yoshino, H., Okauchi, T., Yoshimatsu, K., Ozawa, Y., Sugi, N. H., Nagasu, T., Koyanagi, N., & Kitoh, K. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9902638 · Cited by 322 · cited 4×
“RBM39 is also vital for colorectal cancer cell survival in vitro and in vivo (Han et al., 2017; Owa et al., 1999; Ozawa et al., 2001; SillarsHardebol et al., 2012; Uehara et al., 2017).”
BackgroundInfluentialStructural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
Faust, T. B., Yoon, H., Nowak, R. P., Donovan, K. A., Li, Z., Cai, Q., Eleuteri, N. A., Zhang, T., Gray, N. S., & Fischer, E. S. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0378-3 · Cited by 218 · cited 10×
“Binding of the molecular glue induces conformational changes in DCAF15, leading to selective recruitment of RBM39 as a neosubstrate (Bussiere et al., 2020; Faust et al., 2020; Han et al., 2017).”
BackgroundInfluentialDowhan, D. H., Hong, E. P., Auboeuf, D., Dennis, A. P., Wilson, M. M., Berget, S. M., & O'Malley, B. W. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.025 · Cited by 193 · cited 29×
“Mutations ABBREVIATIONS: AML, acute myeloid leukaemia; AP-1, activating protein-1; CCLE, Cancer Cell Line Encyclopedia; CDK, cyclin-dependent kinase; CQS, chloroquinoxaline sulphonamide; DCAF15, DDB1- and Cul4-associated factor 15; ER, oestrogen receptor; ERRα, oestrogen-related receptor-α; GO, gene ontology; HIF-1α,…”
BackgroundResultInfluentialDu, X., Volkov, O. A., Czerwinski, R. M., Tan, H., Huerta, C., Morton, E. R., Rizzi, J. P., Wehn, P. M., Xu, R., Nijhawan, D., et al. (2019) · Structure · doi:10.1016/j.str.2019.10.005 · Cited by 181
Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15
Ting, T. C., Goralski, M., Klein, K., Wang, B., Kim, J., Xie, Y., & Nijhawan, D. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.079 · Cited by 123
Fukuoka, K., Usuda, J., Iwamoto, Y., Fukumoto, H., Nakamura, T., Yoneda, T., Narita, N., Saijo, N., & Nishio, K. (2001) · Investigational New Drugs · doi:10.1023/a:1010608317361 · Cited by 112 · cited 13×
“Indisulam has been used to treat lung cancer in several preclinical and clinical studies (Tables 1 and S1) (Fukuoka et al., 2001; Ozawa et al., 2001; Talbot et al., 2007).”
BackgroundMethodInfluentialMita, M., Kelly, K. R., Mita, A., Ricart, A. D., Romero, O., Tolcher, A., Hook, L., Okereke, C., Krivelevich, I., Rossignol, D. P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0010 · Cited by 71 · cited 1×
“…2013; Haddad et al., 2004; Hamid et al., 2014; Jotte et al., 2015; Kirkwood et al., 2011; Miller et al., 1997; Milojkovic Kerklaan et al., 2016; Mita et al., 2011; Punt et al., 2001; Raymond et al., 2002; Rigas et al., 1992; Rigas et al., 1995; Ryan et al., 2013; Scagliotti et al., 2012;…”
Punt, C. J. A., Fumoleau, P., van de Walle, B., Faber, M. N., Ravic, M., & Campone, M. (2001) · Annals of Oncology · doi:10.1023/a:1012287111922 · Cited by 57 · cited 1×
“…al., 2004; Hamid et al., 2014; Jotte et al., 2015; Kirkwood et al., 2011; Miller et al., 1997; Milojkovic Kerklaan et al., 2016; Mita et al., 2011; Punt et al., 2001; Raymond et al., 2002; Rigas et al., 1992; Rigas et al., 1995; Ryan et al., 2013; Scagliotti et al., 2012; Siegel-Lakhai et al.,…”
CAPER, a novel regulator of human breast cancer progression
Mercier, I., Gonzales, D. M., Quann, K., Pestell, T. G., Molchansky, A., Sotgia, F., Hulit, J., Gandara, R., Wang, C., Pestell, R. G., et al. (2014) · Cell Cycle · doi:10.4161/cc.28156 · Cited by 45
Simon, G. R., Ilaria, R. L., Sovak, M. A., Williams, C. C., Haura, E. B., Cleverly, A. L., Sykes, A. K., Wagner, M. M., de Alwis, D. P., Slapak, C. A., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1593-0 · Cited by 19 · cited 1×
“…Kerklaan et al., 2016; Mita et al., 2011; Punt et al., 2001; Raymond et al., 2002; Rigas et al., 1992; Rigas et al., 1995; Ryan et al., 2013; Scagliotti et al., 2012; Siegel-Lakhai et al., 2008; Simon et al., 2011; Smyth et al., 2005; Talbot et al., 2007; Terret et al., 2003; Yamada et al., 2005).”
Cited by
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Arginine reprograms metabolism in liver cancer via RBM39
Mossmann, D., Müller, C., Park, S., Ryback, B., Colombi, M., Ritter, N., Weißenberger, D., Dazert, E., Coto-Llerena, M., Nuciforo, S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.09.011 · Cited by 293
Nijhuis, A., Sikka, A., Yogev, O., Herendi, L., Balcells, C., Ma, Y., Poon, E., Eckold, C., Valbuena, G. N., Xu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28907-3 · Cited by 110
Self-citationChallenges in Therapeutically Targeting the RNA‐Recognition Motif
Schmeing, S., & Hart, P. '. (2024) · WIREs RNA · doi:10.1002/wrna.1877 · Cited by 11
Metadata
- Authors
- Xu, Y., Nijhuis, A., & Keun, H. C.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2021-01-03
- Volume
- 179
- Issue
- 12
- Pages
- 2795-2812
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W3108926404
- Cited by
- 90
- References
- 21
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.